Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada.
PLoS One. 2010 Jun 9;5(6):e11031. doi: 10.1371/journal.pone.0011031.
Recombinant interferon treatment can result in several common side effects including fever and injection-site pain. Patients are often advised to use acetaminophen or other over-the-counter pain medications as needed. Little is known regarding the transcriptional changes induced by such co-administration.
METHODOLOGY/PRINCIPAL FINDINGS: We tested whether the administration of acetaminophen causes a change in the response normally induced by interferon-beta treatment. CD-1 mice were administered acetaminophen (APAP), interferon-beta (IFN-beta) or a combination of IFN-beta+APAP and liver and serum samples were collected for analysis. Differential gene expression was determined using an Agilent 22 k whole mouse genome microarray. Data were analyzed by several methods including Gene Ontology term clustering and Gene Set Enrichment Analysis. We observed a significant change in the transcription profile of hepatic cells when APAP was co-administered with IFN-beta. These transcriptional changes included a marked up-regulation of genes involved in signal transduction and cell differentiation and down-regulation of genes involved in cellular metabolism, trafficking and the IkappaBK/NF-kappaB cascade. Additionally, we observed a large decrease in the expression of several IFN-induced genes including Ifit-3, Isg-15, Oasl1, Zbp1 and predicted gene EG634650 at both early and late time points.
CONCLUSIONS/SIGNIFICANCE: A significant change in the transcriptional response was observed following co-administration of IFN-beta+APAP relative to IFN-beta treatment alone. These results suggest that administration of acetaminophen has the potential to modify the efficacy of IFN-beta treatment.
重组干扰素治疗会导致一些常见的副作用,包括发热和注射部位疼痛。患者通常被建议根据需要使用对乙酰氨基酚或其他非处方止痛药。对于这种联合用药引起的转录变化知之甚少。
方法/主要发现:我们测试了对乙酰氨基酚的给药是否会导致干扰素-β治疗正常诱导的反应发生变化。用对乙酰氨基酚(APAP)、干扰素-β(IFN-β)或 IFN-β+APAP 联合给药处理 CD-1 小鼠,并收集肝脏和血清样本进行分析。使用 Agilent 22 k 全小鼠基因组微阵列确定差异基因表达。通过几种方法分析数据,包括基因本体论术语聚类和基因集富集分析。当 APAP 与 IFN-β 联合给药时,我们观察到肝细胞转录谱发生显著变化。这些转录变化包括参与信号转导和细胞分化的基因的显著上调和参与细胞代谢、运输和 IkappaBK/NF-kappaB 级联的基因的下调。此外,我们还观察到几种 IFN 诱导基因的表达水平大幅下降,包括 Ifit-3、Isg-15、Oasl1、Zbp1 和预测基因 EG634650,无论是在早期还是晚期时间点。
结论/意义:与 IFN-β 单独治疗相比,IFN-β+APAP 联合给药后观察到转录反应的显著变化。这些结果表明,对乙酰氨基酚的给药有可能改变 IFN-β 治疗的疗效。